>Go!

Executive Officers and Directors

Executive Leadership

Chairman, President and CEO, Allergan Image

Chairman, President and CEO, Allergan

Brenton L. Saunders

Brent Saunders is Chairman, President and Chief Executive Officer of Allergan plc. Mr. Saunders has served as a Director, CEO and President since July 2014.

  • Brent Saunders is Chairman, President and Chief Executive Officer of Allergan plc. Mr. Saunders has served as a Director, CEO and President since July 2014. He was elected Chairman in 2016. Previously, he served as Chief Executive Officer and President of Forest Laboratories and as a Director of Forest since 2011. Mr. Saunders has significant healthcare industry expertise and a proven track-record leading business transformations and integrations. Prior to Forest, Mr. Saunders was Chief Executive Officer of Bausch + Lomb, a leading global eye health company, serving in this capacity from March 2010 until August 2013. Mr. Saunders also held several leadership positions at Schering-Plough, including the position of President of Global Consumer Health Care, and was named head of integration for the company’s merger with Merck & Co. and for Schering-Plough’s acquisition of Organon BioSciences. Before joining Schering-Plough, Mr. Saunders was a partner and head of Compliance Business Advisory at PricewaterhouseCoopers LLP. Prior to that, he was Chief Risk Officer at Coventry Health Care and Senior Vice President, Compliance, Legal and Regulatory at Home Care Corporation of America. Earlier in his career, Mr. Saunders served as Chief Compliance Officer for the Thomas Jefferson University Health System. Mr. Saunders serves on the Board of Directors of Cisco Systems and RWJBarnabas Health, and is a member of the Business Council and PhRMA. He is also the former Chairman of the New York chapter of the American Heart Association. Mr. Saunders earned his MBA from Temple University School of Business, his J.D. from Temple University School of Law and his bachelor’s degree from the University of Pittsburgh.

EVP & Chief Commercial Officer Image

EVP & Chief Commercial Officer

William Meury

Bill Meury is the Chief Commercial Officer, and has served in this role since May 2016.

  • Mr. Meury previously served as President, Branded Pharma from March 2015 to May 2016. He joined the Company in July 2014 as Executive Vice President, Commercial, North American Brands. He has significant experience in launching and commercializing healthcare products. Prior to joining Allergan, Mr. Meury served as Executive Vice President, Sales and Marketing at Forest Laboratories, Inc. He joined Forest in 1993 and held multiple roles of increasing responsibility in Marketing, New Products, Business Development, and Sales. Before joining Forest, Mr. Meury worked in public accounting for Reznick Fedder & Silverman and in financial reporting for MCI Communications. Mr. Meury is currently on the Board of Directors of several organizations, including The Jed Foundation, International Council of Ophthalmology Foundation, and The Allergan Foundation. Mr. Meury earned his bachelor’s degree in Economics from the University of Maryland.

EVP & Chief Financial Officer Image

EVP & Chief Financial Officer

Matt Walsh

Mr. Walsh joined Allergan in February 2018 as Executive Vice President and Chief Financial Officer.

  • Mr. Walsh brings a unique combination of strong financial experience and a deep understanding of the healthcare industry with a proven track record of managing complex organizations. Prior to joining Allergan, Mr. Walsh served as EVP, CFO at Catalent for 10 years. Before Catalent, Mr. Walsh was President, CFO and Acting CEO at Escala Group, Inc. He previously held a variety of finance leadership roles at GenTek, Inc., including Vice President-Finance & Chief Financial Officer, Vice President & Treasurer and Group Controller. Mr. Walsh is a CFA® charterholder. He received an MBA from Cornell University, SC Johnson School of Management and a Bachelor of Science in Chemical Engineering from Cornell University, College of Engineering.

EVP & Chief Legal Officer and Corporate Secretary Image

EVP & Chief Legal Officer and Corporate Secretary

A. Robert D. Bailey

Bob Bailey is the Chief Legal Officer and Corporate Secretary, and has served in this role since July 2014.

  • Previously, Mr. Bailey served as Senior Vice President, Chief Legal Officer, General Counsel and Corporate Secretary of Forest Laboratories, Inc. Mr. Bailey previously served from 2007 to 2013 as Executive Vice President, Law, Policy and Communications at Bausch + Lomb, and was with the company for more than 16 years. Before joining Bausch + Lomb in 1994, Mr. Bailey was an attorney at Nixon Peabody (formerly Nixon Hargrave Devans & Doyle). Mr. Bailey is a member of the US Chamber Litigation Board of Directors. He earned his law degree from the University of Minnesota and his undergraduate degree from St. Olaf College in Northfield, Minnesota.

EVP & Chief Human Resources Officer Image

EVP & Chief Human Resources Officer

Karen L. Ling, Esq.

Karen Ling is the Chief Human Resources Officer, and has served in this role since July 2014.

  • She previously served as Senior Vice President and Chief Human Resources Officer for Forest Laboratories, Inc. from January to July 2014. Prior to joining Forest, Ms. Ling served as Senior Vice President, Human Resources at Merck & Co., for the company’s Global Human Health and Consumer Care businesses worldwide beginning in November 2011. Previously, she served as Vice President, Compensation and Benefits at Merck and Group Vice President, Global Compensation & Benefits at Schering-Plough (which was acquired by Merck). Prior to joining Schering-Plough in 2008, Ms. Ling spent 14 years at Wyeth Pharmaceuticals in various positions of responsibility in human resources and in Wyeth’s Labor and Employment Department. Before joining Wyeth, Ms. Ling was an attorney at Goldstein and Manello, P.C. in Boston. Ms. Ling is currently a member of the Board of Directors of the Glaucoma Foundation, Inc., a non-for-profit organization. She earned J.D. from Boston University School of Law and a B.A. from Yale University.

EVP & Chief R&D Officer Image

EVP & Chief R&D Officer

C. David Nicholson, PhD

David Nicholson is the Chief R&D Officer, and has served in this role since March 2015.

  • Dr. Nicholson joined the company (then Actavis) as Senior Vice President, Global Brands R&D in August 2014. He has been in research and development in the pharmaceutical industry since 1978. Previously, he served as Chief Technology Officer and EVP, R&D for Bayer CropScience from March 2012 to August 2014; Senior Vice President of Licensing and Knowledge Management at Merck from 2009 to December 2011; and Senior Vice President, responsible for Global Project Management and Drug Safety at Schering-Plough from 2007 to 2009. From 1988 to 2007, Dr. Nicholson held various leadership positions at Organon, where he most recently served as Executive Vice President, R&D and was a member of the company’s Executive Management Committee. Dr. Nicholson earned his B.Sc. from the University of Manchester and his Ph.D. from the University of Wales.

EVP & Chief Communications Officer Image

EVP & Chief Communications Officer

Alex Kelly

Alex Kelly is the EVP, Corporate Affairs and Chief Communications Officer, and has served in this role since April 20, 2015.

  • Previously, Mr. Kelly served as Senior Vice President, Chief Integration Officer since July 2014. In this role, he led the integration of Forest Laboratories following its acquisition by Actavis. He also co-led the integration of Allergan. Prior to joining Actavis, Mr. Kelly was Senior Vice President, Chief Communications Officer, Public Affairs and Investor Relations at Forest Laboratories. In that role, he led Forest’s corporate communications and investor relations programs. While at Forest, Mr. Kelly led the integration of Aptalis Pharma following its acquisition in January 2014. Prior to Forest, Mr. Kelly served as Vice President, Investor Relations at Bausch + Lomb. Mr. Kelly was Senior Vice President, Investor Relations at Merck & Co., Inc. following the combination with Schering-Plough where he led the Global Communications and Investor Relations team. He previously worked for Novartis as Executive Director, Investor Relations, after spending 14 years at Pharmacia, including ten years in pharmaceutical sales and sales management and four years in investor relations. Mr. Kelly currently serves on multiple Boards and Committees, including the California Life Sciences Association, The Allergan Foundation, and the HealthCare Institute of New Jersey. He earned his Bachelor of Science in Pharmacy from Purdue University, where he graduated Cum Laude.

EVP, Global Operations Image

EVP, Global Operations

Wayne R. Swanton

Prior to his current appointment, Mr. Swanton served as Senior Vice President, Global Operations of Allergan.

  • He joined the company (then Watson) in March 2012 as Vice President, Global Supply Chain. Mr. Swanton brings expertise to all aspects of the end-to-end supply chain, including procurement, planning, manufacturing, external supply, quality and distribution. He has extensive leadership experience in global pharmaceutical operations and managing significant business transformations. Prior to joining Allergan, Mr. Swanton held various roles at Abbott Laboratories in finance, supply chain, project management and manufacturing operations in both local and global capacities. Mr. Swanton is a Fellow of the Chartered Association of Certified Accountants, UK.

Directors

Director Image

Director

Nesli Basgoz, M.D.

  • Dr. Basgoz joined the Board of Directors in July 2014 following the Company’s acquisition of Forest Laboratories, Inc., having served as a member of the Board of Directors of Forest beginning 2006. Dr. Basgoz is currently the Associate Chief and Clinical Director, Division of Infectious Diseases at Massachusetts General Hospital (MGH), a role she has held since 2001. In addition, Dr. Basgoz is an Associate Professor of Medicine at Harvard Medical School. Dr. Basgoz earned her MD degree and completed her residency in internal medicine at Northwestern University Medical School. She also completed a fellowship in the Infectious Diseases Division at the University of California at San Francisco. She is board certified in both infectious diseases and internal medicine. The Board of Directors concluded that Dr. Basgoz should serve on the Board of Directors because of her extensive experience in clinical medicine, particularly in the field of infectious diseases and anti-infective therapy, one of our therapeutic areas of focus.

  • Other Public Company Directorships:

    • None

  • Other Directorships:

    • MGH Board of Trustees
    • Partners Healthcare Board of Trustees

  • Previous, Recently-Held Public Company Directorships:

    • Forest Laboratories, Inc.

Director Image

Director

Paul M. Bisaro

  • Mr. Bisaro currently serves as the Executive Chairman of Amneal Pharmaceuticals Inc., a role he assumed in May 2018 upon the merger of Amneal and Impax Laboratories, Inc., where Mr. Bisaro served as President and Chief Executive Officer beginning in March 2017. Prior to joining Impax, Mr. Bisaro served in a number of executive roles at Allergan before his departure from the Company in December 2016, most recently as Executive Chairman of our Board of Directors from July 2014 to October 2016, and before that as our President and Chief Executive Officer and as Chairman of our Board of Directors beginning October 2013; prior to serving as Chairman, he served on the Board of Directors beginning September 2007. Prior to joining the Company, Mr. Bisaro was President, Chief Operating Officer and a member of the Board of Directors of Barr Pharmaceuticals, Inc., a global specialty pharmaceutical company (Barr), from 1999 to 2007. Between 1992 and 1999, Mr. Bisaro served as General Counsel of Barr, and from 1997 to 1999, served in various additional capacities including Senior Vice President – Strategic Business Development. Prior to joining Barr, he was associated with the law firm Winston & Strawn and a predecessor firm, Bishop, Cook, Purcell and Reynolds, from 1989 to 1992.

  • Other Public Company Directorships:

    • Zimmer Biomet Holdings, Inc.
    • Zoetis, Inc.

  • Other Directorships:

    • Board of Visitors of the Catholic University of America’s Columbus School of Law

Director Image

Director

Joseph H. Boccuzi

  • Mr. Boccuzi retired from Spencer Stuart in December 2016 after 24 years of service, where he played a central role in establishing and building the firm’s Life Sciences Practice. He served in positions of increasing responsibility within Spencer Stuart, most recently as a Partner in the firm’s Global Life Sciences, Board and Chief Executive Officer Practices, a role he had held since 1996. Prior to joining Spencer Stuart, Mr. Boccuzi worked in executive search, venture capital and corporate management roles. He served as a consultant with Paul R. Ray & Company, an executive search firm. Prior to that, he worked as a Financial Advisor for Merrill Lynch. Mr. Boccuzi also held several leadership positions at National Patent Development Corporation, a venture capital firm specializing in medical technology and investment throughout the U.S. and worldwide. While there, he managed four medical startup operations serving as chief operating officer, board member and adviser to the board of directors. Prior to that, Mr. Boccuzi worked in sales for Xerox Corporation. The Board of Directors concluded that Mr. Boccuzi should serve on the Board of Directors because of his deep understanding of leadership, talent and compensation issues in the pharmaceutical industry.

Director Image

Director

Christopher W. Bodine

  • Mr. Bodine joined the Board of Directors in 2009. Mr. Bodine retired from CVS Caremark in January 2009 after 24 years with CVS. Prior to his retirement, Mr. Bodine served as President, Healthcare Services of CVS Caremark Corporation, where he was responsible for strategy, business development, trade relations, sales and account management, pharmacy merchandising, marketing, information technology and Minute Clinic. Prior to the merger of CVS Corporation and Caremark Rx, Inc. in March 2007, Mr. Bodine served for several years as Executive Vice President – Merchandising and Marketing of CVS Corporation. Mr. Bodine is active in the pharmaceutical industry, having served on a number of boards and committees, including the Healthcare Leadership Council, RI Quality Institute, National Retail Federation, National Association of Chain Drug Stores (NACDS), and the NACDS Pharmacy Affairs and Leadership Committees. The Board of Directors concluded that Mr. Bodine should serve on the Board of Directors because of his extensive industry experience and knowledge of the needs and operations of our major customers.

  • Other Public Company Directorships:

    • Fred’s Inc.

  • Previous, Recently-Held Public Company

    • Nash Finch

Director Image

Director

Adriane M. Brown

  • Ms. Brown joined the Board of Directors in 2017. She is currently serving as Senior Advisor to Intellectual Ventures LLC (Intellectual Ventures), having served as President and Chief Operating Officer of Intellectual Ventures until 2017. Prior to joining Intellectual Ventures, Ms. Brown served in a number of leadership positions at Honeywell International, Inc. (Honeywell) from 1999-2010, most recently as Senior Vice President, Energy Strategy, and prior to that, as President and CEO of Honeywell’s Transportation Systems global operating group. Prior to joining Honeywell, Ms. Brown had a nearly 20 year career at Corning, Inc. Ms. Brown received her Bachelor of Science in environmental health from Old Dominion University and a Master’s of Science in management (Sloan Fellow) from Massachusetts Institute of Technology. She also received a Doctorate of Humane Letters from Old Dominion University. The Board of Directors concluded that Ms. Brown should serve on the Board of Directors because of her global business experience as a senior executive in technology-rich companies and her experience identifying, protecting and licensing intellectual property.

  • Other Directorships:

    • Pacific Science Center
    • Jobs for America’s Graduates
    • Washington Research Foundation
    • Seattle Chamber of Commerce
    • Numerous Intellectual Ventures-managed fund subsidiaries

  • Previous, Recently-Held Public Company

    • Harman International Industries, Inc.

Lead Independent Director Image

Lead Independent Director

Christopher J. Coughlin

  • Mr. Coughlin joined the Board of Directors in July 2014 following the Company’s acquisition of Forest Laboratories, Inc., having served as a member of the Board of Directors of Forest beginning 2011. Mr. Coughlin began serving as our Lead Independent Director in October 2016. Mr. Coughlin served as Senior Advisor to the CEO and Board of Directors of Tyco until September 2012. Prior to that, he was Executive Vice President and Chief Financial Officer of Tyco International from 2005 to 2010. During his tenure, he played a central role in the separation of Tyco into five independent, public companies. Prior to joining Tyco, he worked as the Chief Operating Officer of the Interpublic Group of Companies from June 2003 to December 2004, as Chief Financial Officer from August 2003 to June 2004 and as a director from July 2003 to July 2004. Previously, Mr. Coughlin was Executive Vice President and Chief Financial Officer of Pharmacia Corporation from 1998 until its acquisition by Pfizer in 2003. Prior to that, he was Executive Vice President of Nabisco Holdings and President of Nabisco International. From 1981 to 1996 he held various positions, including Chief Financial Officer, at Sterling Winthrop. In addition to the directorships listed below, Mr. Coughlin also previously served on the Board of Directors of Interpublic Group of Companies, Monsanto Company and Perrigo Company. The Board of Directors concluded that Mr. Coughlin should serve on the Board of Directors, and as our Lead Independent Director, because his depth of experience in executive leadership roles within complex corporate organizations and his service on public company boards, including in the roles of Chairman and Lead Independent Director, contribute critical risk oversight and management insight to our Board of Directors.

  • Other Public Company Directorships:

    • Alexion Pharmaceuticals, Inc. (Chair of the Audit Committee)

  • Previous, Recently-Held Public Company

    • The Dun & Bradstreet Corp. (Former Chairman of the Board)
    • Hologic, Inc. (Chair of the Audit Committee)
    • Covidien
    • Dipexium
    • Forest Laboratories, Inc.

Director Image

Director

Carol Anthony (John) Davidson

  • Mr. Davidson joined the Board of Directors in May 2018. He retired from Tyco International in September 2012, having served as senior vice president, controller and chief accounting officer since January 2004, where he was responsible for overseeing financial reporting, internal controls, and accounting policies and processes. In this role Mr. Davidson worked as part of Tyco's new senior leadership team in establishing financial integrity, operational excellence and strong ethical practices across Tyco global operations. Prior to joining Tyco in January 2004, Mr. Davidson served as vice president, audit, risk and compliance for Dell Inc. During his six-year career at Dell he also served in other senior capacities including chief compliance officer and vice president and corporate controller. In addition, Mr. Davidson spent 16 years with Eastman Kodak Company where he led the company’s internal audit function and previously served in a variety of accounting and financial leadership roles. He began his career with Arthur Andersen & Co. From 2011 to 2015 he served as a member of the board of trustees of the Financial Accounting Foundation which oversees the FASB and GASB in accounting standards setting. Since 2012, Mr. Davidson has served on the board of governors of the Financial Industry Regulatory Authority (FINRA) which regulates and oversees the US financial industry in the interest of investor protection and market integrity. Mr. Davidson serves as a trustee of University of Rochester, where he earned his MBA in Finance. He earned his BS in Accounting from St. John Fisher College. Mr. Davidson was inducted into the Financial Executives International (FEI) Hall of Fame.

  • Other Directorships:

    • Trustee, University of Rochester
    • Trustee, Garth Fagan Dance

  • Other Public Company Directorships:

    • TE Connectivity Ltd.
    • Legg Mason, Inc.

  • Previous, Recently-Held Public Company Directorships:

    • Pentair Plc
    • DaVita, Inc.

Director Image

Director

Catherine M. Klema

  • Ms. Klema joined the Board of Directors in 2004. She is currently President of Nettleton Advisors LLC, a consulting firm established by Ms. Klema in 2001. Prior to establishing her firm, Ms. Klema served as Managing Director, Healthcare Investment Banking, at SG Cowen Securities from 1997 to 2001. Ms. Klema also served as Managing Director, Healthcare Investment Banking, at Furman Selz LLC from 1994 until 1997, and was employed by Lehman Brothers from 1987 until 1994. Ms. Klema served as a director of Pharmaceutical Product Development, Inc., a global contract research organization, from 2000 to 2011.

  • Other Public Company Directorships:

    • None

  • Other Directorships:

    • Montefiore Health System Board of Trustees

Director Image

Director

Peter J. McDonnell, M.D.

  • Dr. McDonnell joined the Board of Directors in March 2015 following the Company’s acquisition of Allergan, Inc., having served as a member of the Allergan, Inc. Board of Directors from 2013. Dr. McDonnell has been the Director and William Holland Wilmer Professor of the Wilmer Eye Institute of the Johns Hopkins University School of Medicine since 2003. Dr. McDonnell has also served as the Chief Medical Editor of Ophthalmology Times since 2004, and has served on the editorial boards of numerous ophthalmology journals. Dr. McDonnell also served as the Assistant Chief of Service at the Wilmer Institute from 1987 to 1988. Dr. McDonnell also serves as the President and a director of the National Alliance for Eye and Vision Research and the Alliance for Eye and Vision Research and as the Chief Medical Editor of the Ophthalmology Times. He served as a consultant to the United States Department of Health and Human Services in 1996. Dr. McDonnell served as a full-time faculty at the University of Southern California from 1988 until 1999, where he advanced to the rank of professor in 1994. The Board of Directors has concluded that Dr. McDonnell should serve on the Board of Directors because he provides our Board of Directors with wide-ranging expertise in ophthalmology, one of our therapeutic areas of focus. He is widely recognized as an international leader in corneal transplantation, laser refractive surgery and the treatment of dry eye.

  • Other Public Company Directorships:

    • None

  • Other Directorships:

    • Alliance for Eye and Vision Research
    • National Alliance for Eye and Vision Research
    • PanAmerican Ophthalmological Foundation

  • Previous, Recently-Held Public Company

    • Allergan, Inc.

Director Image

Director

Patrick J. O’Sullivan

  • Mr. O’Sullivan joined the Board of Directors in October 2013 following the Company’s acquisition of Warner Chilcott plc, having served as a member of the Warner Chilcott Board of Directors from 2009. He retired from LEO Pharma A/S in 2006, after 30 years of service with LEO. Prior to his retirement, Mr. O’Sullivan served in positions of increasing responsibility with LEO, most recently as the Chief Executive Officer of LEO Pharma Ireland and as a director of LEO. He also served as a director of LEO Pharmaceuticals Ltd. UK, LEO Pharma SA France and The LEO Foundation. Mr. O’Sullivan is a registered pharmacist, a member and honorary fellow of the Pharmaceutical Society of Ireland and a Knight of the Order of the Dannebrog. The Board of Directors concluded that Mr. O’Sullivan should serve on the Board of Directors because of his demonstrated management ability at senior levels within the pharmaceutical industry, his knowledge of the financial, operational and strategic requirements of a successful international business, and his understanding of the fundamentals of the healthcare industry.

  • Other Public Company Directorships:

    • Amarin Corporation plc (Chair of the Nominating and Corporate Governance Committee)

  • Previous, Recently-Held Public Company

    • Warner Chilcott Public Limited Company

Director Image

Director

Fred G. Weiss

  • Mr. Weiss joined the Board of Directors in 2000. Mr. Weiss is currently the managing director of the consulting firm FGW Consultancy LLC and was previously the managing director of FGW Associates, Inc., a position he held beginning in 1997. Prior to joining FGW he served as an executive for Warner-Lambert for nearly 20 years, most recently as Vice President, Planning, Investment and Development. Mr. Weiss also served from 2000 to January 2017 as Vice-Chairman of the Board of Directors and Chairman of the Audit Committee of numerous BlackRock-sponsored mutual funds. The Board of Directors concluded that Mr. Weiss should serve on the Board of Directors because of his financial expertise and experience in strategic planning and corporate development. Mr. Weiss also brings audit and compliance experience to the Board from his previous role as Chairman of the Audit Committee of numerous BlackRock-sponsored mutual funds.

  • Other Public Company Directorships:

    • None

  • Other Directorships:

    • Michael J. Fox Foundation for Parkinson’s Research (Treasurer and Chair of the Finance Committee)

Electronic Enrollment
Allergan Shareholders: